Cargando…

High Prevalence of Metabolic Syndrome Features in Patients Previously Treated for Nonfunctioning Pituitary Macroadenoma

OBJECTIVE: Patients treated for nonfunctioning pituitary macroadenoma (NFMA) with suprasellar extension show disturbed sleep characteristics, possibly related to hypothalamic dysfunction. In addition to hypopituitarism, both structural hypothalamic damage and sleep restriction per se are associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Joustra, Sjoerd D., Claessen, Kim M. J. A., Dekkers, Olaf M., van Beek, André P., Wolffenbuttel, Bruce H. R., Pereira, Alberto M., Biermasz, Nienke R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946551/
https://www.ncbi.nlm.nih.gov/pubmed/24608862
http://dx.doi.org/10.1371/journal.pone.0090602
_version_ 1782306662253592576
author Joustra, Sjoerd D.
Claessen, Kim M. J. A.
Dekkers, Olaf M.
van Beek, André P.
Wolffenbuttel, Bruce H. R.
Pereira, Alberto M.
Biermasz, Nienke R.
author_facet Joustra, Sjoerd D.
Claessen, Kim M. J. A.
Dekkers, Olaf M.
van Beek, André P.
Wolffenbuttel, Bruce H. R.
Pereira, Alberto M.
Biermasz, Nienke R.
author_sort Joustra, Sjoerd D.
collection PubMed
description OBJECTIVE: Patients treated for nonfunctioning pituitary macroadenoma (NFMA) with suprasellar extension show disturbed sleep characteristics, possibly related to hypothalamic dysfunction. In addition to hypopituitarism, both structural hypothalamic damage and sleep restriction per se are associated with the metabolic syndrome. However, the prevalence of the metabolic syndrome in patients with NFMA is not well established. Our objective was to study the prevalence and risk factors for (components of) the metabolic syndrome in patients treated for NFMA. DESIGN: The metabolic syndrome (NCEP-ATP III criteria) was studied in an unselected cohort of 145 NFMA patients (aged 26–88yr, 44% female) in long-term remission after treatment, receiving adequate stable hormone replacement for any pituitary deficiencies. The results were compared to population data of 63,995 Dutch inhabitants by standardization (LifeLines cohort study). RESULTS: NFMA patients showed increased risk for reduced HDL-cholesterol (SMR 1.59, 95% CI 1.13–2.11), increased triglyceride levels (SMR 2.31, 95% CI 1.78–2.90) and the metabolic syndrome (SMR 1.60, 95% CI 1.22–2.02), but not for increased blood pressure, waist circumference or hyperglycemia. Preoperative visual field defects independently affected the risk for increased blood pressure (OR 6.5, 95% CI 1.9–22.2), and hypopituitarism was associated with a body mass index - dependent risk for increased waist circumference (OR 1.6, 95% CI 1.2–2.2) and the metabolic syndrome (OR 1.4, 95% CI 1.0–1.9). CONCLUSIONS: Patients treated for NFMA are increased at risk for developing the metabolic syndrome, mainly due to decreased HDL-cholesterol and increased triglycerides. Risk factors included hypopituitarism and preoperative visual field defects. Hypothalamic dysfunction may explain the metabolic abnormalities, in addition to intrinsic imperfections of hormone replacement therapy. Additional research is required to explore the relation between derangements in circadian rhythmicity and metabolic syndrome in these patients.
format Online
Article
Text
id pubmed-3946551
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-39465512014-03-10 High Prevalence of Metabolic Syndrome Features in Patients Previously Treated for Nonfunctioning Pituitary Macroadenoma Joustra, Sjoerd D. Claessen, Kim M. J. A. Dekkers, Olaf M. van Beek, André P. Wolffenbuttel, Bruce H. R. Pereira, Alberto M. Biermasz, Nienke R. PLoS One Research Article OBJECTIVE: Patients treated for nonfunctioning pituitary macroadenoma (NFMA) with suprasellar extension show disturbed sleep characteristics, possibly related to hypothalamic dysfunction. In addition to hypopituitarism, both structural hypothalamic damage and sleep restriction per se are associated with the metabolic syndrome. However, the prevalence of the metabolic syndrome in patients with NFMA is not well established. Our objective was to study the prevalence and risk factors for (components of) the metabolic syndrome in patients treated for NFMA. DESIGN: The metabolic syndrome (NCEP-ATP III criteria) was studied in an unselected cohort of 145 NFMA patients (aged 26–88yr, 44% female) in long-term remission after treatment, receiving adequate stable hormone replacement for any pituitary deficiencies. The results were compared to population data of 63,995 Dutch inhabitants by standardization (LifeLines cohort study). RESULTS: NFMA patients showed increased risk for reduced HDL-cholesterol (SMR 1.59, 95% CI 1.13–2.11), increased triglyceride levels (SMR 2.31, 95% CI 1.78–2.90) and the metabolic syndrome (SMR 1.60, 95% CI 1.22–2.02), but not for increased blood pressure, waist circumference or hyperglycemia. Preoperative visual field defects independently affected the risk for increased blood pressure (OR 6.5, 95% CI 1.9–22.2), and hypopituitarism was associated with a body mass index - dependent risk for increased waist circumference (OR 1.6, 95% CI 1.2–2.2) and the metabolic syndrome (OR 1.4, 95% CI 1.0–1.9). CONCLUSIONS: Patients treated for NFMA are increased at risk for developing the metabolic syndrome, mainly due to decreased HDL-cholesterol and increased triglycerides. Risk factors included hypopituitarism and preoperative visual field defects. Hypothalamic dysfunction may explain the metabolic abnormalities, in addition to intrinsic imperfections of hormone replacement therapy. Additional research is required to explore the relation between derangements in circadian rhythmicity and metabolic syndrome in these patients. Public Library of Science 2014-03-07 /pmc/articles/PMC3946551/ /pubmed/24608862 http://dx.doi.org/10.1371/journal.pone.0090602 Text en © 2014 Joustra et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Joustra, Sjoerd D.
Claessen, Kim M. J. A.
Dekkers, Olaf M.
van Beek, André P.
Wolffenbuttel, Bruce H. R.
Pereira, Alberto M.
Biermasz, Nienke R.
High Prevalence of Metabolic Syndrome Features in Patients Previously Treated for Nonfunctioning Pituitary Macroadenoma
title High Prevalence of Metabolic Syndrome Features in Patients Previously Treated for Nonfunctioning Pituitary Macroadenoma
title_full High Prevalence of Metabolic Syndrome Features in Patients Previously Treated for Nonfunctioning Pituitary Macroadenoma
title_fullStr High Prevalence of Metabolic Syndrome Features in Patients Previously Treated for Nonfunctioning Pituitary Macroadenoma
title_full_unstemmed High Prevalence of Metabolic Syndrome Features in Patients Previously Treated for Nonfunctioning Pituitary Macroadenoma
title_short High Prevalence of Metabolic Syndrome Features in Patients Previously Treated for Nonfunctioning Pituitary Macroadenoma
title_sort high prevalence of metabolic syndrome features in patients previously treated for nonfunctioning pituitary macroadenoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946551/
https://www.ncbi.nlm.nih.gov/pubmed/24608862
http://dx.doi.org/10.1371/journal.pone.0090602
work_keys_str_mv AT joustrasjoerdd highprevalenceofmetabolicsyndromefeaturesinpatientspreviouslytreatedfornonfunctioningpituitarymacroadenoma
AT claessenkimmja highprevalenceofmetabolicsyndromefeaturesinpatientspreviouslytreatedfornonfunctioningpituitarymacroadenoma
AT dekkersolafm highprevalenceofmetabolicsyndromefeaturesinpatientspreviouslytreatedfornonfunctioningpituitarymacroadenoma
AT vanbeekandrep highprevalenceofmetabolicsyndromefeaturesinpatientspreviouslytreatedfornonfunctioningpituitarymacroadenoma
AT wolffenbuttelbrucehr highprevalenceofmetabolicsyndromefeaturesinpatientspreviouslytreatedfornonfunctioningpituitarymacroadenoma
AT pereiraalbertom highprevalenceofmetabolicsyndromefeaturesinpatientspreviouslytreatedfornonfunctioningpituitarymacroadenoma
AT biermasznienker highprevalenceofmetabolicsyndromefeaturesinpatientspreviouslytreatedfornonfunctioningpituitarymacroadenoma